PMV Pharmaceuticals published Phase I results for rezatapopt, a small molecule p53 reactivator targeting the TP53 Y220C mutation, in the New England Journal of Medicine. Across 77 heavily pretreated patients with advanced solid tumors, rezatapopt showed tolerability and objective responses in patients with the Y220C mutation, consistent with restoration of wild‑type p53 function. Dose escalation established a recommended Phase II dose with infrequent dose‑limiting toxicities. Biomarker analyses supported selective binding to the Y220C pocket. PMV plans a registrational Phase II strategy and aims for an NDA filing in platinum‑resistant/refractory ovarian cancer in early 2027. The NEJM publication provides peer‑reviewed validation of mechanism and clinical activity, marking a noteworthy example of precision targeting of a tumor suppressor reactivation strategy.